Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesPayablesProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China SXT Pharmaceuticals (SXTC) Other Non-Current Assets (2018 - 2024)

China SXT Pharmaceuticals has reported Other Non-Current Assets over the past 7 years, most recently at -$120122.0 for Q3 2024.

  • For Q3 2024, Other Non-Current Assets fell 300.68% year-over-year to -$120122.0; the TTM value through Sep 2024 reached -$120122.0, down 300.68%, while the annual FY2024 figure was $8.3 million, 4.88% down from the prior year.
  • Other Non-Current Assets for Q3 2024 was -$120122.0 at China SXT Pharmaceuticals, down from $8.3 million in the prior quarter.
  • Over five years, Other Non-Current Assets peaked at $9.5 million in Q1 2022 and troughed at -$263108.0 in Q3 2020.
  • A 5-year average of $5.0 million and a median of $8.3 million in 2024 define the central range for Other Non-Current Assets.
  • Biggest five-year swings in Other Non-Current Assets: skyrocketed 3639.18% in 2021 and later crashed 300.68% in 2024.
  • Year by year, Other Non-Current Assets stood at -$263108.0 in 2020, then skyrocketed by 3639.18% to $9.3 million in 2021, then crashed by 100.66% to -$61775.0 in 2022, then skyrocketed by 196.9% to $59857.0 in 2023, then crashed by 300.68% to -$120122.0 in 2024.
  • Business Quant data shows Other Non-Current Assets for SXTC at -$120122.0 in Q3 2024, $8.3 million in Q1 2024, and $59857.0 in Q3 2023.